August 12, 2009Open Access
View Full PaperPremature Release of Data from Clinical Trials of Ezetimibe
Key Points
Key points are not available for this paper at this time.
Abstract
The authors describe the unexpected finding of a cancer risk in ongoing clinical trials of the cholesterol-lowering drug ezetimibe. They discuss the implications of these events for how we address new, unanticipated scientific evidence, especially in the area of drug safety.